
The company Lundbeck wants to buy an American biotech company for about 17 billion kroner. (Archive photo). Photo: Ida Guldbæk Arentsen/Ritzau Scanpix
Lundbeck’s billion-dollar epilepsy drug buy
Lundbeck is acquiring Longboard Pharmaceuticals for $2.5 billion to secure an epilepsy drug, Bexicaserin, targeting rare conditions like Dravet and Lennox-Gastaut syndromes. Bexicaserin has blockbuster potential with projected annual sales of $2 billion and a planned launch for the end of 2028....
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?